← Leaderboards
Eliza F Chakravarty
Stanford University
$3,534,424
Attributed
$3,534,424
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $390.4K · FY2006–22$500K$375K$250K$125K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$3,534,424 · 10
By mechanism
P30$3,249,513 · 2
R03$271,543 · 1
M01$13,368 · 7
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Elizabeth D Mellins$6,432,167
Others in their field
Top investigators on “Resources”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$688,986,350
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Eric S Lander · Whitehead Institute For Biomedical Res$341,717,134
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$311,514,701
Research focus
ResourcesFundingResearch PersonnelBaseRepositoryLupusCohortAutoimmune DiseasesClinical DataParticipantSamplingOklahomaEnrollmentProtocols DocumentationGrantUnited States National Institutes Of HealthHuman Subject ResearchCollectionClinical ResearchInformation SystemsBiobankHuman ResourcesInstitutesPrograms
Grant awards (21)
Clinical Characterization and Biorepository Core$306,671
P30 · FY2022 · AR · contact PI
Clinical Characterization and Biorepository Core$306,671
P30 · FY2021 · AR · contact PI
Clinical Characterization and Biorepository Core$306,671
P30 · FY2020 · AR · contact PI
Clinical Characterization and Biorepository Core$306,671
P30 · FY2019 · AR · contact PI
Clinical Characterization and Biorepository Core$306,791
P30 · FY2018 · AR · contact PI
Clinical Characterization and Biorepository Core$287,376
P30 · FY2017 · AR · contact PI
Clinical Characterization and Biorepository Core$288,617
P30 · FY2016 · AR · contact PI
Antibody Mediated Spontaneous Abortion in Lupus Pregnancies$85,159
R03 · FY2016 · AR · contact PI
Clinical Characterization and Biorepository Core$288,619
P30 · FY2015 · AR · contact PI
Antibody Mediated Spontaneous Abortion in Lupus Pregnancies$84,579
R03 · FY2015 · AR · contact PI
Clinical Characterization and Biorepository Core$288,619
P30 · FY2014 · AR · contact PI
Antibody Mediated Spontaneous Abortion in Lupus Pregnancies$101,805
R03 · FY2014 · AR · contact PI
Clinical Characterization and Biorepository Core$274,188
P30 · FY2013 · AR · contact PI
Clinical Characterization and Biorepository Core$288,619
P30 · FY2012 · AR · contact PI
EFFICACY OF ABATACEPT IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS$2,617
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: RITUXIMAB IN SUBJECTS WITH MODERATE TO SEVERE SYSTEMIC LUPUS ERY$910
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: RITUXIMAB IN SUBJECTS WITH ISN/RPS CLASS III OR IV LUPUS NEPHRIT$455
M01 · FY2008 · RR · contact PI
RITUXIMAB IN SUBJECTS WITH MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS$6,437
M01 · FY2007 · RR · contact PI
RITUXIMAB IN SUBJECTS WITH ISN/RPS CLASS III OR IV LUPUS NEPHRITIS$585
M01 · FY2007 · RR · contact PI
TREATMENT OF ACTIVE SLE AND THE PREVENTION OF SUBSEQUENT LUPUS FLARES$585
M01 · FY2007 · RR · contact PI
RITUXIMAB IN SUBJECTS WITH MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS$1,779
M01 · FY2006 · RR · contact PI